In CBD tau pathology in the amygdala is probably mild in very early disease stages in the absence of secondary pathology [40], and eventually develops more when grain pathology, either as feature of CBD [53], or as additional AGD, is also present. The gene discussed is MAPT; the disease is argyrophilic grain disease.